Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Team Grant: E-Rare Joint Transnational Call

McGill University

$224,378.00

Endoplasmic Reticulum Proteostasis to rescue Alpha1 AntiTrypsin Deficiency (acronym ERAAT) This is a proposal to the -Rare Joint Transnational Call for Proposals 2017 "Transnational Research Projects for Innovative Therapeutic Approaches for Rare Diseases"

FY 2017-18

Summary
Alpha1-antitrypsin deficiency (ATD) is a rare disease caused by mutations in the alpha1-antitrypsin (A1AT) genes leading to improperly folded protein products unable to be secreted, and that in some instances aggregate in hepatocyte endoplasmic reticulum (ER). The normal function of A1AT is to be transported to the lung where it acts as an inhibitor of neutrophil elastase. Z mutant alpha1-antitrypsin (ZA1AT) is retained in the ER by cellular quality control mechanisms and aggregates in this compartment. The consequences are severe health issues such as a loss-of-function defect in the lungs leading to lung emphysemas and chronic obstructive pulmonary disease (COPD) due the lack of circulating active A1AT. In the liver, the accumulation of ZA1AT through loop-sheet polymerization of soluble monomers leads to a proteotoxic gain-of-function, subsequently linked to deficient export from the ER. This aggregation can cause liver fibrosis and cirrhosis and subsequently hepatic failure. The current therapeutic option for ZA1AT is transplantation. To date, there exists no other effective pharmacological treatment alternative for ATD. Research from the Chevet laboratory showed that selected activation of the IRE1 arm of the Unfolded Protein Response (UPR) improved the secretion of functionally active ZA1AT. This provides the proof of principle supporting the hypothesis that increasing ER proteostasis is a novel strategy to decrease proteotoxicity in the liver and to neutralize proteolytic activity in the lung in ATD.
Program
Team Grant: E-Rare Joint Transnational Call
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
373006
Name
Thomas David Y
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Partnername
German Federal Ministry of Research, Technology and Space (Berlin); Fonds de recherche du Québec - Santé (FRQS); Fonds de recherche du Québec - Santé (FRQS); The French National Research Agency (France); National Research, Development and Innovation Office (Budapest, Hungary)
Instname2
Genetics
Theme2
Biomedical
Prcname2
Special Cases
Projecttitle
Endoplasmic Reticulum Proteostasis to rescue Alpha1 AntiTrypsin Deficiency (acronym ERAAT) This is a proposal to the -Rare Joint Transnational Call for Proposals 2017 "Transnational Research Projects for Innovative Therapeutic Approaches for Rare Diseases"
Programtype2
Operating Grants
Orgnameinp2
McGill University
Cihramount2
$224,378
Cihrequipment2
$0
Programname2
Team Grant: E-Rare Joint Transnational Call
Keyworddelim
Alpha-1-Antrypsin Deficiency; Cell Based Screening; Ire1 Kinase/Rnaase; Liver And Lung Problems; Medicinal Chemistry; Protein Misfolding; Protein Quality Control; Protein Trafficking Diseases; Serpinopathies; Unfolded Protein Response
Abstract
Alpha1-antitrypsin deficiency (ATD) is a rare disease caused by mutations in the alpha1-antitrypsin (A1AT) genes leading to improperly folded protein products unable to be secreted, and that in some instances aggregate in hepatocyte endoplasmic reticulum (ER). The normal function of A1AT is to be transported to the lung where it acts as an inhibitor of neutrophil elastase. Z mutant alpha1-antitrypsin (ZA1AT) is retained in the ER by cellular quality control mechanisms and aggregates in this compartment. The consequences are severe health issues such as a loss-of-function defect in the lungs leading to lung emphysemas and chronic obstructive pulmonary disease (COPD) due the lack of circulating active A1AT. In the liver, the accumulation of ZA1AT through loop-sheet polymerization of soluble monomers leads to a proteotoxic gain-of-function, subsequently linked to deficient export from the ER. This aggregation can cause liver fibrosis and cirrhosis and subsequently hepatic failure. The current therapeutic option for ZA1AT is transplantation. To date, there exists no other effective pharmacological treatment alternative for ATD. Research from the Chevet laboratory showed that selected activation of the IRE1 arm of the Unfolded Protein Response (UPR) improved the secretion of functionally active ZA1AT. This provides the proof of principle supporting the hypothesis that increasing ER proteostasis is a novel strategy to decrease proteotoxicity in the liver and to neutralize proteolytic activity in the lung in ATD.
Competitiondate
201706
Approvedterm2
3 yrs 0 mth
Pinamesdelim
Thomas, David Y
Approvedterm
3 ans 0 mois
Cihrcontribution2
Institute of Genetics~ $224,378~ $0~
McGill University - $224,378 Grant (2017-18) | Canada Spends